Clinical implications of fibroblast activation protein in patients with colon cancer

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1736-1741

  Henry, Leonard R ^a   Lee, Hyung Ok ^a   Lee, John S ^a   Klein Szanto, Andres ^a   Watts, Perry ^a   Ross, Eric A ^a   Chen, Wen Tien ^b   Cheng, Jonathan D ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; SEPRASE; FAP PROTEIN, HUMAN; SERINE PROTEINASE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ANALYTIC METHOD; ARTICLE; CANCER PATIENT; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STAINING; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; XENOTRANSPLANTATION; ADENOCARCINOMA; ADULT; ANIMAL; C57BL MOUSE; CELL STRAIN HT29; COLON TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; MOUSE MUTANT; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, NEOPLASM; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MIDDLE AGED; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250189539     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1746     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Hurwitz H, Fehrenbacher L, Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
4. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362: 841-4.
5. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274:36505-12.
6. Pineiro-Sanchez ML, Goldstein LA, Dodt J, et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997;272:7595-601.
7. Montironi R, Diamanti L, Thompson D, Bartels HG, Bartels PH. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol 1996;30:191-200.
8. Ghersi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002;277: 29231-41.
9. Levy MT, McCaughan GW, Marinos G, Gorrell MD. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 2002;22:93-101.
10. Cheng JD, Dunbrack RL, Jr., Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002; 62:4767-72.
11. Cheng JD, Valianou M, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005;4: 351-60.
12. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990;87:7235-9.
13. Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994; 12:1193-203.
14. Tanswell P, Garin-Chesa P, Rettig WJ, et al. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol 2001;51:177-80.
15. Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47.
16. Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003;26:44-8.
17. Adams S, Miller GT, Jones B. Dipeptidyl peptidase inhibitor PT-100 suppresses tumor growth in vivo and enhances chemotherapy in mice [abstract]. Clin Cancer Res 2003;9:C109.
18. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004;64:5471-80.
19. Uprichard MJ, O'Day SJ, Pavlick AC, et al. Phase 2 study of talabostat and cisplatin in stage IV melanoma. Proc Am Assoc Cancer Res 2005;24:abstract 7563.
20. Cunningham C, Richards D, Salgia R, et al. Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC. Proc Am As soc Cancer Res 2005;24:abstract 7120.
21. Redman BG, Ernstoff MS, Gajewski TF, et al. Phase 2 trial of talabostat in stage IV melanoma. Proc Am Assoc Cancer Res 2005;24:abstract 7570.
22. Iwasa S, Jin X, Okada K, Mitsumata M, Ooi A. Increased expression of seprase, a membrane-type serine protease, is associatedwith lymph node metastasis in human colorectal cancer. Cancer Lett 2003; 199:91-8.
23. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/ seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001;95:67-72.
24. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560-7.
25. Brown RE, Lun M, Prichard JW , Blasick TM, Zhang PL. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 2004;34:251-62.
26. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 2005;104:962-7.
27. Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004;64:2712-6.
28. Jin X, Iwasa S, Okada K, Mitsumata M, Ooi A. Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. Anticancer Res 2003;23:3195-8.
29. Mori Y, Kono K, Matsumoto Y, et al. The expression of a type II transmembrane serine protease (seprase) in human gastric carcinoma. Oncology 2004;67:411-9.
30. Okada K, Chen WT, Iwasa S, et al. Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology 2003;65:363-70.